期刊
ENDOCRINE-RELATED CANCER
卷 18, 期 1, 页码 R1-R14出版社
BIOSCIENTIFICA LTD
DOI: 10.1677/ERC-10-0070
关键词
-
资金
- Canadian Institutes of Health Research (CIHR)
- CancerCare Manitoba Foundation (CCMF)
- Canadian Breast Cancer Foundation (CBCF)
- Manitoba Breast Tumor Bank
- Canadian Tumor Repository Network
Multiple sites of phosphorylation on human estrogen receptor alpha (ER alpha) have been identified by a variety of methodologies. Now with the emerging availability of phospho-site-specific antibodies to ER alpha, the relevance of phosphorylation of ER alpha in human breast cancer in vivo is being explored. Multiple phosphorylated sites in ER alpha can be detected in multiple breast tumor biopsy samples, providing evidence of their relevance to human breast cancer in vivo. Published data suggest that the detection in primary breast tumors of phosphorylation at some sites in ER alpha is associated with a better clinical outcome while phosphorylation at other sites is associated with a poorer clinical outcome most often in patients who have been treated with tamoxifen. This suggests the hypothesis that phospho-profiling of ER alpha in human breast tumors to establish an 'ER alpha phosphorylation code', may be a more accurate marker of prognosis and/or response to endocrine therapy in human breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据